Immunology Quality Assessment (IQA) Program

A competitive cost reimbursement, level of effort (term) type contract was awarded, for the period of performance of September 30, 2021 through September 29, 2022 (Base Period), and a total period of performance (including base period and all options) of September 30, 2021 through September 29, 2028. Upon analysis of the type of work and all associated costs involved, a fixed-price type contract was not feasible due to the absence of precise specifications and difficulties in estimating costs with accuracy. Based upon the uncertainties involved, the Government would assume undue risk in attempting to fit a relatively dynamic (science responsive and result-driven) requirement into a fixed-price environment. A fixed-price contract would be disadvantageous to the Government, since it does not provide the Government with the flexibility that is needed to responsively and responsibly shift with the evolving needs of the requirement.

This award notice is in relation to Solicitation #75N93020R00007.